TobyMaherMD
Pulmonology • Los Angeles, CAInterstitial Lung Diseases
Professor of Clinical Medicine and Director of Interstitial Lung Disease
Dr. Maher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1520 San Pablo St
Ste 1000
Los Angeles, CA 90033Phone+1 323-442-5100
Summary
- I am a pulmonologist specializing in the diagnosis and treatment of interstitial lung diseases including; idiopathic pulmonary fibrosis, sarcoidosis, lung disease related to connective tissue diseases and rheumatoid arthritis, chronic hypersensitivity pneumonitis, histiocytosis and LAM.
Education & Training
University of Southampton Faculty of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2020 - 2026
Clinical Trials
- Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial Start of enrollment: 2020 Dec 17
Roles: Contact
- LYT-100 in Post-acute COVID-19 Respiratory Disease Start of enrollment: 2020 Dec 11
- Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Start of enrollment: 2022 Sep 08
- Join now to see all
Publications & Presentations
PubMed
- 214 citationsPD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 productionLindsay J. Celada, Jonathan A. Kropski, Jose D. Herazo-Maya, Weifeng Luo, Amy Creecy
Science Translational Medicine. 2018-09-26 - 243 citationsIncreased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injuryChris J. Scotton, Malvina A. Krupiczojc, Melanie Königshoff, Paul F. Mercer, Y. C. Gary Lee
The Journal of Clinical Investigation. 2009-09-01 - 29 citationsThe causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study.Carl J Reynolds, Fabiola Del Greco M, Richard J Allen, Carlos Flores, R Gisli Jenkins
The European Respiratory Journal. 2023-05-01
Press Mentions
AI-Driven Drug Discovery Achieves Milestone with Insilico Medicine’s Phase IIa Success in Treating Pulmonary FibrosisSeptember 26th, 2024- Insilico Reports Positive Initial Trial Data for AI-Designed IPF DrugSeptember 20th, 2024
- Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AISeptember 18th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
